Quest Diagnostics: A Solid Investment or a Risky Bet?

Motley Fool's Stock Advisor analyst team, in a September 4, 2025 video, notably excluded Quest Diagnostics (NYSE: DGX) from its current list of 10 best stock recommendations, despite the broader Motley Fool organization holding and recommending DGX. This suggests a nuanced or potentially mixed outlook from the prominent advisory service regarding DGX's immediate investment potential, with their top analyst picks favoring other opportunities.

Analysis

The primary insight from the Motley Fool publication is that its flagship 'Stock Advisor' analyst team has explicitly excluded Quest Diagnostics (NYSE: DGX) from its most recent list of the '10 best stocks to buy now,' as of September 4, 2025. This omission, which carries a negative sentiment score of -0.2 for the ticker, is particularly noteworthy as the article also states that the broader Motley Fool organization holds positions in and recommends DGX. This creates a conflicting signal, suggesting a divergence of opinion where the elite analyst team sees more compelling opportunities for 'monster returns' elsewhere, despite a standing long-term recommendation from the parent firm. The article provides no fundamental basis for the exclusion, such as earnings, growth, or valuation metrics for DGX, instead using the omission as a marketing tool to promote its subscription service by highlighting past successful picks like Netflix and Nvidia. The low market impact score of 0.2 indicates this specific analyst viewpoint is not expected to be a major catalyst for the stock.

Key Decisions for Investors

• Investors should treat the exclusion of Quest Diagnostics from the 'Stock Advisor' top 10 list as a notable negative sentiment indicator from an influential source, suggesting a potential lack of near-term catalysts relative to other investment opportunities.
• Given the conflicting signal where the broader Motley Fool entity holds DGX while its analyst team passes on it, it would be prudent to review the stock's current fundamentals and growth outlook independently rather than relying solely on this recommendation.
• This analyst action warrants a re-evaluation of DGX's position within a portfolio, particularly its weighting against other healthcare or growth stocks that may be seen as having more immediate upside potential.